Clinical Trials Listing Service

Asthma

Last updated: December 12, 2022
Sponsor: N/A
Overall Status: Active - Recruiting

Phase

2

Condition

Asthma

Treatment

N/A

Clinical Study ID

TX291177
D7552C00001
  • Ages 18-55
  • All Genders

Study Summary

A Phase 2, Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD5718 Given Orally Once Daily for Twelve Weeks in Adults with Moderate-to-Severe Uncontrolled Asthma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • be 18 to 55 years of age
  • have moderate to severe uncontrolled asthma
  • have documented diagnosis of asthma 12 months prior to screening visit

Exclusion

Exclusion Criteria:

  • A severe asthma exacerbation within 8 weeks of randomization.
  • Participants with a significant COVID-19 illness within 6 months of enrollment:
  • Participants with a diagnosis of COVID-19 pneumonia based on radiological assessment
  • Participants with a diagnosis of COVID-19 requiring hospitalization and/or oxygen supplementation therapy
  • Galactose intolerance, Lapp lactase deficiency, or glucose-galactose metabolism

Study Design

Study Start date:
Estimated Completion Date:

Study Description

  • Condition: Asthma

  • Clinical Trial Identifier: N/A

  • Sponsor: AstraZeneca

Connect with a study center

  • AMR Lexington

    Lexington, Kentucky 40509
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.